| Role of the Keap1–Nrf2 pathway in cancer HM Leinonen, E Kansanen, P Pölönen, M Heinäniemi, AL Levonen Advances in cancer research 122, 281-320, 2014 | 191 | 2014 |
| Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity O Dufva, J Koski, P Maliniemi, A Ianevski, J Klievink, J Leitner, P Pölönen, ... Blood, The Journal of the American Society of Hematology 135 (9), 597-609, 2020 | 186 | 2020 |
| Immunogenomic landscape of hematological malignancies O Dufva, P Pölönen, O Brück, MAI Keränen, J Klievink, J Mehtonen, ... Cancer Cell 38 (3), 380-399. e13, 2020 | 157 | 2020 |
| Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ... Haematologica 105 (3), 708, 2020 | 139 | 2020 |
| Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia LE Montefiori, S Bendig, Z Gu, X Chen, P Pölönen, X Ma, A Murison, ... Cancer discovery 11 (11), 2846-2867, 2021 | 110 | 2021 |
| Dysregulation of the Keap1–Nrf2 pathway in cancer HM Leinonen, E Kansanen, P Pölönen, M Heinäniemi, AL Levonen Biochemical Society Transactions 43 (4), 645-649, 2015 | 83 | 2015 |
| Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma P Pölönen, A Jawahar Deen, HM Leinonen, HK Jyrkkänen, S Kuosmanen, ... Oncogene 38 (50), 7473-7490, 2019 | 80 | 2019 |
| Analysis of primary microRNA loci from nascent transcriptomes reveals regulatory domains governed by chromatin architecture M Bouvy-Liivrand, A Hernández de Sande, P Pölönen, J Mehtonen, ... Nucleic acids research 45 (17), 9837-9849, 2017 | 55 | 2017 |
| Signalling input from divergent pathways subverts B cell transformation LN Chan, MA Murakami, ME Robinson, R Caeser, T Sadras, J Lee, ... Nature 583 (7818), 845-851, 2020 | 50 | 2020 |
| The effects of sequence variation on genome-wide NRF2 binding—new target genes and regulatory SNPs SM Kuosmanen, S Viitala, T Laitinen, M Peräkylä, P Pölönen, ... Nucleic acids research 44 (4), 1760-1775, 2016 | 43 | 2016 |
| Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ... Blood 141 (13), 1610-1625, 2023 | 42 | 2023 |
| Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia Leukemia 37 (518-528. doi: 10.1038/s41375-022-0), 2023 | 42 | 2023 |
| In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen, ... Blood cancer journal 7 (9), e604-e604, 2017 | 33 | 2017 |
| Hemap: an interactive online resource for characterizing molecular phenotypes across hematologic malignancies P Pölönen, J Mehtonen, J Lin, T Liuksiala, S Häyrynen, S Teppo, ... Cancer research 79 (10), 2466-2479, 2019 | 29 | 2019 |
| Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma H Sallinen, S Janhonen, P Pölönen, H Niskanen, OH Liu, A Kivelä, ... BMC cancer 19, 1-11, 2019 | 24 | 2019 |
| Profiling of primary and mature miRNA expression in atherosclerosis-associated cell types PR Moreau, V Tomas Bosch, M Bouvy-Liivrand, K Õunap, T Örd, ... Arteriosclerosis, thrombosis, and vascular biology 41 (7), 2149-2167, 2021 | 20 | 2021 |
| Data-driven characterization of molecular phenotypes across heterogeneous sample collections J Mehtonen, P Pölönen, S Häyrynen, O Dufva, J Lin, T Liuksiala, ... Nucleic acids research 47 (13), e76-e76, 2019 | 20 | 2019 |
| A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies J Härkönen, P Pölönen, AJ Deen, I Selvarajan, HR Teppo, EY Dimova, ... Redox Biology 61, 102644, 2023 | 15 | 2023 |
| Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers O Dufva, S Gandolfi, J Huuhtanen, O Dashevsky, H Duàn, K Saeed, ... Immunity 56 (12), 2816-2835. e13, 2023 | 13 | 2023 |
| Comprehensive genome characterization of childhood T-ALL links oncogene activation mechanism and subtypes to prognosis P Pölönen, A Elsayed, D Di Giacomo, L Montefiori, S Kimura, J Myers, ... Blood 140 (Supplement 1), 1727-1729, 2022 | 8 | 2022 |
